Bold Therapeutics, a Caada-based clinical-stage biopharmaceutical company developing BOLD-100, announced on Thursday that it has extended its option agreement with an undisclosed publicly traded South Korean biopharmaceutical company for development and commercialisation rights to BOLD-100 in South Korea.
The extension is intended to further strengthen cooperation between these companies, and support the addition of five clinical trial sites in South Korea: Seoul National University Hospital (PI: Do-Youn Oh); Samsung Medical Center (PI: Joon Oh Park); Severance Hospital (PI: Sun Young Rha); National Cancer Center (PI: Yongjun Cha); and Kangbuk Samsung Hospital (KBSMC) (PI: Dong-Hoe Koo).
The company's BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that alters the unfolded protein response via selective GRP78 inhibition; and induces reactive oxygen species that causes DNA damage and cell cycle arrest. BOLD-100 has received Orphan Drug Designations from the United States Food and Drug Administration in both gastric (stomach) and pancreatic cancers, and Bold Therapeutics is likely to receive one or more Breakthrough Therapy Designations for BOLD-100 in 2022.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval